Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

Study:

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)

Rationale:

n/a

Purpose:

Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT. This study will compare the effectiveness of two new types of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow donated from family members with only partially matched bone marrow; and, one that uses two partially matched cord blood units.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Acute Lymphocytic Leukemia
Acute Myelogenous Leukemia
Burkitt`s Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Drug: Biological/Vaccine: Haploidentical BMT
Drug: Double Cord Blood Transplantation
Phase 3

Verified by Medical College of Wisconsin February, 2013

Sponsored by: Medical College of Wisconsin
Information provided by: Medical College of Wisconsin
ClinicalTrials.gov identifier: NCT01597778

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Mary Horowitz, MD, MS., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site